{"id":408491,"date":"2021-01-05T08:33:23","date_gmt":"2021-01-05T13:33:23","guid":{"rendered":"http:\/\/www.marketnewsdesk.com\/?p=408491"},"modified":"2021-01-05T08:33:23","modified_gmt":"2021-01-05T13:33:23","slug":"myovant-sciences-to-present-at-the-39th-annual-j-p-morgan-healthcare-conference","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/myovant-sciences-to-present-at-the-39th-annual-j-p-morgan-healthcare-conference\/","title":{"rendered":"Myovant Sciences to Present at the 39th Annual J.P. Morgan Healthcare Conference"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"left\">BASEL, Switzerland, Jan.  05, 2021  (GLOBE NEWSWIRE) &#8212; Myovant Sciences\u00a0(NYSE: MYOV), a healthcare company focused on redefining care for women and for men, today announced that David Marek, chief executive officer of Myovant Sciences, Inc., will present at the virtual 39th Annual\u00a0J.P. Morgan Healthcare Conference\u00a0on\u00a0Tuesday, January 12, 2021 at 2:50 p.m. Pacific Time.<\/p>\n<p align=\"left\">A live webcast of the presentation will be accessible on the Events page under the <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=TmZ0Oxz93fZ63mfcNYYCGkdQ7TRZyugb9sz0aQQ-xDry51jKd0JJt6b9VOBCMI2l19ORcVcrA9BxgTprTWnnSs7Y58BzAHIEm-AfOUvnlXo=\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">Investors &amp; Media<\/a> section of the Myovant website at <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=TO6bOqnRzRBJZw-SV3yKA48iI34XSNktenrUyeL78m3vLmrk8_UPkbAZU-UJYEJDLaOlscPHxPGKUvRVL5YVbw==\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">www.myovant.com<\/a>.<\/p>\n<p>\n        <strong>About\u00a0Myovant Sciences\u00a0<\/strong><br \/>\n        <br \/>Myovant Sciences\u00a0aspires to redefine care for women and for men through purpose-driven science, empowering medicines, and transformative advocacy. Our lead product candidate, relugolix, is a once-daily, oral GnRH receptor antagonist. Relugolix (120 mg) is FDA-approved as ORGOVYX\u2122\u00a0for adult patients with advanced prostate cancer. Relugolix combination tablet (relugolix 40 mg, estradiol 1.0 mg, and norethindrone acetate 0.5 mg) is under regulatory review in\u00a0Europe\u00a0and the\u00a0U.S.\u00a0for women with uterine fibroids and is under development for women with endometriosis. We are also developing MVT-602, an oligopeptide kisspeptin-1 receptor agonist, which has completed a Phase 2a study for female infertility as part of assisted reproduction.\u00a0Sumitovant Biopharma, Ltd., a wholly owned subsidiary of Sumitomo Dainippon Pharma Co., Ltd., is our majority shareholder. For more information, please visit our website at\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=TO6bOqnRzRBJZw-SV3yKA_yIILNDcHblqJXgKxzILY72nGAVtZ-2bfXxS0_SNA_s6mFH3kv4lhfbMuhxaCS0Vg==\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">www.myovant.com<\/a>. Follow\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=zB0gpX2b1w2lM9_krXfmpk-colNQDJBjd4hww2dWF6B7VsN9OIMnUsIPk0kmpfTIgpPU1jqAkuTEXC9ehs4Cdg==\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">@Myovant<\/a>\u00a0on Twitter and\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=kdOuKoFUyM2c0VnzeeiDdeiPlUFEMNdy2X2OD4vytCPHCU6h4Shg_AjIDMn6Rc4N3idhRs877bamfB7u-9ITbB7fogG9HJ3i2UtCr-iQ9lp66otZpdGERu4fju9zoZLXPC_auPYkd0E_gkdbzYT2bfCuPMtpOw7IihNYVfPEY8EnO4mPw8XDW81mFBkQaounRIO4C7g5JXIh5GSkdY25OkM0m4siWlQQyvL3Q7QobRnrMqnUgdgsENVc0B9bM-pd2fAhjCaGkETVzMP3OJztYHMKnCdPlWCVUB9PkdoU4yVaN04y5qGfppPcC-1gy8UG-6gv7zvC36B4NiqjuqpThwpH9a0CzvKJYA8WmR6O6mBbNsyAZP0wFMwzeyBDYCriWAsCzw1XovabLoDrfzU1A9YfvzVcWQJIKiQejzmMeXnYrcf1-cdMVtK6iIdP-qvZkGC2EH_mPhapKrXvD6KiEA==\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">LinkedIn<\/a>.<\/p>\n<p>\n        <strong>Investor Contact:<\/strong><br \/>\n        <br \/>Ryan Crowe<br \/>Vice President, Investor Relations <br \/>Myovant Sciences, Inc.<br \/>+1 (650) 781-9106<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=-K-0eCUAusO7e9W7b_YBxlodh7SaO9XEPT9pQX66r0Z6o-BB7CGmSPyqGJHg2KvLTukAD8UnMk960PSbbR8mXV5CQYSQrkgGR-h3zmSlI9c=\" rel=\"nofollow noopener noreferrer\" target=\"_blank\"><u>investors@myovant.com<\/u><\/a><\/p>\n<p>\n        <strong>Media Contact:<\/strong><br \/>\n        <br \/>Albert Liao\u00a0<br \/>Director, Corporate Communications<br \/>Myovant Sciences, Inc.<br \/>+1 (650) 410-3055<br \/><u><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=XuxNwQql44AAfnWul2GSLDMRzIDeirXJgihTHlGyFokO5fO2Odjpi1Rpvc5pmsviPHP_vXSLdVHBfwBRt710tw==\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">media@myovant.com<\/a><\/u><\/p>\n<p>      <img loading=\"lazy\" decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODEyMDQ0MyMzOTA0MjgwIzIxNzcyNDg=\" width=\"1\" height=\"1\" \/><br \/>\n      <br \/>\n      <img loading=\"lazy\" decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/ml.globenewswire.com\/release\/track\/55ab880e-fed6-461f-afa8-6e97729fa24a\" width=\"1\" height=\"1\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>BASEL, Switzerland, Jan. 05, 2021 (GLOBE NEWSWIRE) &#8212; Myovant Sciences\u00a0(NYSE: MYOV), a healthcare company focused on redefining care for women and for men, today announced that David Marek, chief executive officer of Myovant Sciences, Inc., will present at the virtual 39th Annual\u00a0J.P. Morgan Healthcare Conference\u00a0on\u00a0Tuesday, January 12, 2021 at 2:50 p.m. Pacific Time. A live webcast of the presentation will be accessible on the Events page under the Investors &amp; Media section of the Myovant website at www.myovant.com. About\u00a0Myovant Sciences\u00a0 Myovant Sciences\u00a0aspires to redefine care for women and for men through purpose-driven science, empowering medicines, and transformative advocacy. Our lead product candidate, relugolix, is a once-daily, oral GnRH receptor antagonist. Relugolix (120 mg) is FDA-approved as ORGOVYX\u2122\u00a0for adult patients with &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/myovant-sciences-to-present-at-the-39th-annual-j-p-morgan-healthcare-conference\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Myovant Sciences to Present at the 39th Annual J.P. Morgan Healthcare Conference&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-408491","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Myovant Sciences to Present at the 39th Annual J.P. Morgan Healthcare Conference - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/myovant-sciences-to-present-at-the-39th-annual-j-p-morgan-healthcare-conference\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Myovant Sciences to Present at the 39th Annual J.P. Morgan Healthcare Conference - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"BASEL, Switzerland, Jan. 05, 2021 (GLOBE NEWSWIRE) &#8212; Myovant Sciences\u00a0(NYSE: MYOV), a healthcare company focused on redefining care for women and for men, today announced that David Marek, chief executive officer of Myovant Sciences, Inc., will present at the virtual 39th Annual\u00a0J.P. Morgan Healthcare Conference\u00a0on\u00a0Tuesday, January 12, 2021 at 2:50 p.m. Pacific Time. A live webcast of the presentation will be accessible on the Events page under the Investors &amp; Media section of the Myovant website at www.myovant.com. About\u00a0Myovant Sciences\u00a0 Myovant Sciences\u00a0aspires to redefine care for women and for men through purpose-driven science, empowering medicines, and transformative advocacy. Our lead product candidate, relugolix, is a once-daily, oral GnRH receptor antagonist. Relugolix (120 mg) is FDA-approved as ORGOVYX\u2122\u00a0for adult patients with &hellip; Continue reading &quot;Myovant Sciences to Present at the 39th Annual J.P. Morgan Healthcare Conference&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/myovant-sciences-to-present-at-the-39th-annual-j-p-morgan-healthcare-conference\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2021-01-05T13:33:23+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODEyMDQ0MyMzOTA0MjgwIzIxNzcyNDg=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/myovant-sciences-to-present-at-the-39th-annual-j-p-morgan-healthcare-conference\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/myovant-sciences-to-present-at-the-39th-annual-j-p-morgan-healthcare-conference\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Myovant Sciences to Present at the 39th Annual J.P. Morgan Healthcare Conference\",\"datePublished\":\"2021-01-05T13:33:23+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/myovant-sciences-to-present-at-the-39th-annual-j-p-morgan-healthcare-conference\\\/\"},\"wordCount\":261,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/myovant-sciences-to-present-at-the-39th-annual-j-p-morgan-healthcare-conference\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODEyMDQ0MyMzOTA0MjgwIzIxNzcyNDg=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/myovant-sciences-to-present-at-the-39th-annual-j-p-morgan-healthcare-conference\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/myovant-sciences-to-present-at-the-39th-annual-j-p-morgan-healthcare-conference\\\/\",\"name\":\"Myovant Sciences to Present at the 39th Annual J.P. Morgan Healthcare Conference - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/myovant-sciences-to-present-at-the-39th-annual-j-p-morgan-healthcare-conference\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/myovant-sciences-to-present-at-the-39th-annual-j-p-morgan-healthcare-conference\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODEyMDQ0MyMzOTA0MjgwIzIxNzcyNDg=\",\"datePublished\":\"2021-01-05T13:33:23+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/myovant-sciences-to-present-at-the-39th-annual-j-p-morgan-healthcare-conference\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/myovant-sciences-to-present-at-the-39th-annual-j-p-morgan-healthcare-conference\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/myovant-sciences-to-present-at-the-39th-annual-j-p-morgan-healthcare-conference\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODEyMDQ0MyMzOTA0MjgwIzIxNzcyNDg=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODEyMDQ0MyMzOTA0MjgwIzIxNzcyNDg=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/myovant-sciences-to-present-at-the-39th-annual-j-p-morgan-healthcare-conference\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Myovant Sciences to Present at the 39th Annual J.P. Morgan Healthcare Conference\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Myovant Sciences to Present at the 39th Annual J.P. Morgan Healthcare Conference - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/myovant-sciences-to-present-at-the-39th-annual-j-p-morgan-healthcare-conference\/","og_locale":"en_US","og_type":"article","og_title":"Myovant Sciences to Present at the 39th Annual J.P. Morgan Healthcare Conference - Market Newsdesk","og_description":"BASEL, Switzerland, Jan. 05, 2021 (GLOBE NEWSWIRE) &#8212; Myovant Sciences\u00a0(NYSE: MYOV), a healthcare company focused on redefining care for women and for men, today announced that David Marek, chief executive officer of Myovant Sciences, Inc., will present at the virtual 39th Annual\u00a0J.P. Morgan Healthcare Conference\u00a0on\u00a0Tuesday, January 12, 2021 at 2:50 p.m. Pacific Time. A live webcast of the presentation will be accessible on the Events page under the Investors &amp; Media section of the Myovant website at www.myovant.com. About\u00a0Myovant Sciences\u00a0 Myovant Sciences\u00a0aspires to redefine care for women and for men through purpose-driven science, empowering medicines, and transformative advocacy. Our lead product candidate, relugolix, is a once-daily, oral GnRH receptor antagonist. Relugolix (120 mg) is FDA-approved as ORGOVYX\u2122\u00a0for adult patients with &hellip; Continue reading \"Myovant Sciences to Present at the 39th Annual J.P. Morgan Healthcare Conference\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/myovant-sciences-to-present-at-the-39th-annual-j-p-morgan-healthcare-conference\/","og_site_name":"Market Newsdesk","article_published_time":"2021-01-05T13:33:23+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODEyMDQ0MyMzOTA0MjgwIzIxNzcyNDg=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/myovant-sciences-to-present-at-the-39th-annual-j-p-morgan-healthcare-conference\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/myovant-sciences-to-present-at-the-39th-annual-j-p-morgan-healthcare-conference\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Myovant Sciences to Present at the 39th Annual J.P. Morgan Healthcare Conference","datePublished":"2021-01-05T13:33:23+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/myovant-sciences-to-present-at-the-39th-annual-j-p-morgan-healthcare-conference\/"},"wordCount":261,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/myovant-sciences-to-present-at-the-39th-annual-j-p-morgan-healthcare-conference\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODEyMDQ0MyMzOTA0MjgwIzIxNzcyNDg=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/myovant-sciences-to-present-at-the-39th-annual-j-p-morgan-healthcare-conference\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/myovant-sciences-to-present-at-the-39th-annual-j-p-morgan-healthcare-conference\/","name":"Myovant Sciences to Present at the 39th Annual J.P. Morgan Healthcare Conference - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/myovant-sciences-to-present-at-the-39th-annual-j-p-morgan-healthcare-conference\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/myovant-sciences-to-present-at-the-39th-annual-j-p-morgan-healthcare-conference\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODEyMDQ0MyMzOTA0MjgwIzIxNzcyNDg=","datePublished":"2021-01-05T13:33:23+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/myovant-sciences-to-present-at-the-39th-annual-j-p-morgan-healthcare-conference\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/myovant-sciences-to-present-at-the-39th-annual-j-p-morgan-healthcare-conference\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/myovant-sciences-to-present-at-the-39th-annual-j-p-morgan-healthcare-conference\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODEyMDQ0MyMzOTA0MjgwIzIxNzcyNDg=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODEyMDQ0MyMzOTA0MjgwIzIxNzcyNDg="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/myovant-sciences-to-present-at-the-39th-annual-j-p-morgan-healthcare-conference\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Myovant Sciences to Present at the 39th Annual J.P. Morgan Healthcare Conference"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/408491","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=408491"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/408491\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=408491"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=408491"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=408491"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}